annual meeting program - American Society of Clinical Oncology

Monday, June 7, 2010
Brd. 28C Catumaxomab observational study to investigate efficacy and safety profile
in clinical practice. (Abstract #TPS156)
V. Kunzmann, R. G. Linke, P. Ruf, H. Lindhofer, M. Hennig, M. M. Essing
Brd. 28D Phase I trial of CCL21 gene modified dendritic cells in non-small cell lung
cancer. (Abstract #TPS157)
J. M. Lee, E. B. Garon, F. Baratelli, D. Schaue, P. S. Pak, W. D. Wallace, R. Suh,
F. Abtin, G. Zeng, S. M. Dubinett
Brd. 28E New approaches in dendritic cell vaccination design and efficacy tests for
patients with advanced ovarian cancer: Prospects for a phase I clinical
study. (Abstract #TPS158)
M. Imhof
Brd. 28F An intersubject dose-escalation study of tesetaxel administered orally once
every 3 weeks and once weekly for 3 consecutive weeks in patients with
advanced or metastatic solid tumors. (Abstract #TPS159)
M. Beeram, S. C. Novick, A. Qureshi, A. Patnaik, K. Papadopoulos, A. W. Tolcher
Brd. 28G Dose-escalation phase I study of NKTR-105, a novel pegylated form of
docetaxel. (Abstract #TPS160)
E. Calvo, U. Hoch, D. J. Maslyar, A. W. Tolcher
Brd. 28H Treating HIV� patients for non-AIDS-defining cancers (NADCs) in the era of
targeted chemotherapy: An AIDS malignancy consortium study of sunitinib
in patients on ART. (Abstract #TPS161)
J. F. Deeken, R. T. Mitsuyasu, R. F. Little, S. P. Ivy, R. F. Ambinder, M. A. Rudek,
J. Y. Lee, P. C. Moore, K. Mosby, B. J. Dezube
Brd. 29A Use of a human ribonuclease variant, QBI-139, for the treatment of cancer.
(Abstract #TPS162)
L. E. Strong, J. A. Kink, B. Mei, M. N. Shahan, R. T. Raines
Brd. 29B Phase I study of dasatinib in combination with bevacizumab in advanced
solid tumors. (Abstract #TPS163)
G. Kim, C. M. Annunziata, G. A. Sarosy, L. M. Minasian, S. A. Prindiville, J.
Zujewski, L. Otten, J. Squires, N. D. Houston, E. C. Kohn
Brd. 29C A multicenter, open-label phase Ib/II study to assess the safety and clinical
activity of intravenous combretastatin A1 diphosphate (OXi4503) as
monotherapy in subjects with primary or secondary hepatic tumor burden.
(Abstract #TPS164)
P. N. Mainwaring, J. Lickliter, M. P. Brown, M. Millward, D. J. Chaplin, Z. Goldberg
Brd. 30A Attempt to improve the safety of development studies with a new design for
phase I combination trials of targeted therapies: The PARASOL trial.
(Abstract #TPS165)
S. Negrier, D. Pérol, J. Soria, S. Chabaud, S. Metzger, B. Escudier
Brd. 30B Phase I trial of everolimus and gemcitabine for patients with solid tumors
refractory to standard therapy and for a cohort of patients with
cholangiocarcinoma/gallbladder cancer. (Abstract #TPS166)
B. A. Costello, Y. Qi, M. J. Borad, G. P. Kim, D. W. Northfelt, C. Erlichman, S. R.
Alberts
Brd. 30C Selective inhibition of proliferating endothelial cells: A phase � study of the
novel organoarsenical compound GSAO in patients with advanced solid
tumors. (Abstract #TPS167)
G. Kumaran, M. R. Middleton, Y. K. Zee, L. McGuigan, A. R. Clamp, P. J. Hogg, A.
Jackson, G. J. Parker, A. L. Harris, G. C. Jayson
Brd. 31A Targeting fanconi anemia (FA) repair pathway deficiency for treatment with
PARP inhibitors. (Abstract #TPS168)
W. Zhao, W. Duan, M. E. Leon, A. P. Chen, G. Sofletea, J. Thurmond, B.
Ramaswamy, D. O’Malley, T. S. Bekaii-Saab, M. A. Villalona-Calero
319
MONDAY